Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages

  Rumi, Elisa ^a   Milosevic, Jelena D ^b   Casetti, Ilaria ^a   Dambruoso, Irene ^a   Pietra, Daniela ^a   Boveri, Emanuela ^a   Boni, Marina ^a   Bernasconi, Paolo ^c   Passamonti, Francesco ^d   Kralovics, Robert ^b   Cazzola, Mario ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIVERSITY OF PAVIA   (Italy)

^d AO Ospedale di Circolo e Fondazione Macchi Varese   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; JANUS KINASE 2; PCM1 JAK2 FUSION PROTEIN; RUXOLITINIB; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ABSENCE OF SIDE EFFECTS; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BONE MARROW CELL; CASE REPORT; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CHRONIC DISEASE; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPASSIONATE USE; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; ERYTHROID CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUSION GENE; GENETIC ASSOCIATION; HEMATOPOIESIS; HUMAN; LEUKEMIA REMISSION; LEUKOCYTOSIS; MOLECULAR PATHOLOGY; OLIGOMERIZATION; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOCYTOPENIA; X CHROMOSOME INACTIVATION;

ADULT; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; FEMALE; GENE REARRANGEMENT; HUMANS; HYPEREOSINOPHILIC SYNDROME; JANUS KINASES; ONCOGENE PROTEINS, FUSION; PYRAZOLES; REMISSION INDUCTION; TRANSLOCATION, GENETIC;

EID: 84890463961     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.4370     Document Type: Article

References (16)

1. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC, 2008
2. James C, Ugo V, Le Couédic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148, 2005
3. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005
4. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
5. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787-798, 2012
6. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
7. Verstovsek S, Kantarjian HM, Estrov Z, et al: Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood 120:1202-1209, 2012
8. Reiter A, Walz C, Watmore A, et al: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65:2662-2667, 2005
9. Bousquet M, Quelen C, De Mas V, et al: The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24:7248-7252, 2005
10. Dargent JL, Mathieux V, Vidrequin S, et al: Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes. Eur J Haematol 86:87-90, 2011
11. Prochorec-Sobieszek M, Nasilowska-Adamska B, Borg K, et al: Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: A distinct clinical, pathological and genetic entity with potential treatment target? Leuk Lymphoma 53:1824-1827, 2012
12. Lierman E, Selleslag D, Smits S, et al: Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 120:1529-1531, 2012
13. Hoeller S, Walz C, Reiter A, et al: PCM1-JAK2-fusion: A potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets 15:53-62, 2011
14. Thiele J, Kvasnicka HM, Facchetti F, et al: European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128-1132, 2005
15. Heiss S, Erdel M, Gunsilius E, et al: Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol 36:1148-1151, 2005
16. Cortes J, Hochhaus A, Hughes T, et al: Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 29:524-531, 2011